Member Info for HereforHemo

Micky It’s been a long hard road with this share, and you are certainly not alone in struggling to keep your sanity. Stay strong mate and remember the lyrics “you never count your money when you’re sitting at the table, they’ll be time enough for counting when the dealings done”. Not long now my friend.

Wundr wher Tuan the illiterate is nou the price is gning up? Seems to have disappeared up his arse again. Mayb c him in a fu mure mnths?

OnetoOne reinforces what we already know. You would think you don’t employ staff and expand manufacturing facilities if you weren’t extremely confident the FDA were happy with HEMO CAR-T wasn’t commercially viable as a treatment. Only a matter of time before this goes to the moon. Tick tock.

Knowing Vlad it’ll be referring to Pelosi, certainly nothing to do with Hemogenyx.

August, another month closer. The clean rooms will be certified for GMP cell therapy manufacturing this month, Professor Coen Van Besien joins Hemogenyx as Medical Director on the 19th I think and WuXi complete the Lentivirus, if not this month certainly next month. Everything is set for Hemogenyx to commence their 3 manufacturing runs for HEMO CAR-T next month, which with analytics are anticipated to take 1 month per run, and to be completed by end of November. On completion the IND will be submitted to the FDA, early December is my understanding, and shortly after clinical trials can begin. Important to note that when submitting the IND to the FDA Hemogenyx will be able to demonstrate at this early stage that HEMO CAR-T actually works as an effective cure for AML. With the CDX antibody Master line with Selexis also being imminent , and CBR in vitro testing also expected to be announced, this is indeed a very exciting month for all holders. Be interesting to see how soon those sitting on the sidelines remain so, as when volume does return it would be no surprise to see HEMO jump 40% in a day. I’m certainly looking forward to the next 3-6 months. GLA

Tuan you really are an imbecile. With their other product candidates ongoing just starting a clinical trial for CAR-T will rerate the company to a £70M+ mcap, that’s before any major takes an interest. Investors can derisk or hold for gold upon results, it’s not rocket science. For me, if the FDA allow human trials to commence as HEMO expect them to, it’s a sure sign it will work and save many lives. That’s priceless but if a cost were to put on it a billion dollars would be fair. Don’t think they’ll ever have to dilute shareholders again myself, but if you do continue with your moronic comments and invest elsewhere. You won’t be missed.

Tuan ‘when will we?’ What the **** has it got to do with you, you’ve never been invested in Hemogenyx in your life. Run along little boy.

After years of patience from investors we are finally entering what should be a very rewarding time. Only days away from August and that is the time the clean rooms are certified for GMP cell therapy manufacturing. It’s obvious no coincidence that the esteemed scientist Professor Coen Van Besien joins Hemogenyx as Medical Director next month to coincide with having a fully functioning certified laboratory. With WuXi having completed the DNA and now working on the Lentivirus (to be completed in Aug/Sept) everything is set for Hemogenyx to commence their 3 manufacturing runs for HEMO CAR-T from September this year, which with analytics are anticipated to take 1 month per run, and to complete them by November. On completion the IND will be submitted to the FDA and shortly after clinical trials can begin early 2023. Important to note that when submitting the IND to the FDA Hemogenyx will be able to demonstrate at this early stage that HEMO CAR-T actually works in killing AML, which is why it’s worth the extra time taken in the manufacturing runs to analyse the results in full before submission. In parallel with this the CDX antibody Master line with Selexis will also be completed either next week or early August, a key stage before IND application. Finally the CBR work with an unnamed partner for in vitro testing is also expected to be announced. Personally I think with any or all of the above candidates it’s highly probable that non dilutive financing, extended collaborations and or licensing agreements will be announced in parallel as progress is made. I would urge all not to panic with the current SP. A little more patience and the next few weeks and months really should see everyone ( and I mean everyone) in profit and investors finally being able to look forwards rather than ruminate about the past. Obviously just my take on things so please do your own research and make decisions suitable for you and you alone. GLA.

Mr I it was Vlad who said the CDX master cell line would be completed in July, then added maybe August to give him some leeway. So it’s imminent. The CBR in vitro testing has been going on for months so that’s also imminent. The CAR-T clean rooms will be certified by the middle of next month when the manufacturing director joins so updates on that will also be soon, so yes I’m confident.

Mr India, your post is wrong on every level. Firstly you can’t ‘suppress’ news, it’s illegal. If something has happened thar has a material effect on the SP they are legally obliged to release it. Secondly they can’t just magic an update if nothing has happened! The CDX Master cell line with Selexis is nearing completion, you’ll hear in the next couple of weeks, partnership’s are being arranged, CAR-T is progressing to the clinic and CBR in vitro tests are being completed. You’ll hear when any of the above are COMPLETED not before. They don’t run the company for your benefit but for the benefit of their patients. Much better to absolutely ensure everything works and nobody dies and lives are ultimately saved. Have patience or move on.

JHFH it’s the Master Cell line update up next for CDX. Vlad stated July then added maybe August, so it’s very close. Might not impact the SP but it will it it coincides with a partner announcement to accelerate it into clinical trials. The same with CBR. Vlad answered a tweet ‘could CBR treat all mutations of Covid within a year?’ with ‘probably’. That suggests to me he’s highly confident of the in vitro tests and that the unnamed partner will take it forward quickly.

Like many I’m well down on my HEMO investment, in fact to date it’s been the worst company I’ve ever invested in by far. In one way I’ve been fortunate with the collapse as I’ve had the money to average down, although every purchase I’ve made I’ve lost money on the current SP, on paper at least. However I’ve no intention of selling any of my shares as I still think there’s better days ahead, hopefully anyway. Personally I’m looking forward to the Master Cell line work being completed with Selexis in the next few weeks for their CDX Antibody, as I think Hemogenyx will sub license it when complete in order to accelerate it into clinical trials. I’m also looking forward to the CBR in vitro results as again I think the unnamed partner is likely to license the platform from Hemogenyx if the results are successful, allowing Hemogenyx to fully focus on what is likely to be a billion dollar product on its own, HEMO CAR-T. So I’m hoping for CDX and CBR announcements to return my lost money and for CAR-T to return me to profit in November as people start loading up in anticipation of IND in December. I’ll then hold through clinical trials and CDX IND application and probably cash in at that point. If all goes according to plan this will be my last ever investment. Whatever happens I’ll be drinking a **** load of beer when I’m finally out, hopefully with a few of you. You never know we might actually be smiling!

Pretty sure none is shorting Hemogenyx at this price. Far more likely to be individuals who have overstretched and run out of time and just need to release some cash. I would like to think most if not all that were going to sell already have and I fully expect Hemogenyx to rise this week and beyond.

I’m sure he doesn’t! It’s probably him that’s sold just over a million getting around 1.2p, as any of his sells usually come with a negative comment. Wow that’s some piece of business. Lol.

Social Indeed, probably completion of the Master Cell line for their CDX antibody next up later this month. Feels like momentum is building and as that buffoon Johnson said ‘once the herd moves, it moves’ lol.

Don’t think having a CFD position closed could be classified as selling? Besides he stated that had happened at the time, it was no secret. I wouldn’t make this out to be who to trust on content HT, because if it’s a contest between JHFH and you, you’ll probably come third.

Why does anyone care who sold what and when and who’s got the biggest dick? Everyone will either make or lose money, depending on their entry and exit points, but why are people so obsessed with other peoples holdings? Personally I don’t give a toss. Perhaps somewhere down the line we can actually have a post on Hemogenyx? Just an idea.

Thought I’d post this again as it was drowned out by some love island chat from two individuals.

I’d just say this to current holders and any new investors thinking of buying in for the first time.
Firstly, for those thinking there is not going to be any news from Hemogenyx for six months, that’s factually incorrect. What we do know from Vlad’s Webinar is that the Master Cell line work for their CDX Antibody in collaboration with Selexis will either be completed this month or next. This is important as a) it’s a major step forward in ensuring they have another candidate suitable for clinical trials b) there’s a fair chance that they’ll license it to someone to take it forward quickly c) if they don’t license it it’s probable there’s a collaboration with a partner and the chance of up front revenue. Secondly, we know Hemogenyx are working with an unnamed parter to prove CBR works in vitro, initially for the live virus of Covid. This work has been ongoing for a while now so it’s probable we’ll hear the results sooner rather than later. If the results are positive, it’s a potential paradigm shift in the treatment of all viral infections and a totally unique approach for the market. Again, successful results are very likely to have partners queuing up to either assist Hemogenyx taking it forward quickly or more likely to license it from Hemogenyx to take it forward themselves. As has been discussed, Hemogenyx might just license it for Covid and have the potential to license cures for other viral diseases to other partners, depending on how much someone is willing to pay for the technology. Lastly there is CAT-T, which we know is Hemogenyx main focus at the moment and Hemogenyx are doing everything possible to get their IND application completed in December. That being the case, it’s probable that if investors are waiting for this alone they’ll either be loading up in early December or maybe as soon as mid November. If it’s the latter then that’s barely over sixteen weeks away with updates on CDX and CBR to come beforehand. Add in potential partnerships, collaborations, licensing deals and non dilutive finance they’re working on, and the fact they are already fully funded for the next twelve months, I think the future is a lot rosier than some are making out. That’s why I bought more today anyway, and I’ll keep buying all the way down if holders don’t have the sticky fingers I have and it is a real pleasure taking them off you at these prices. Whatever you think of the above, DYOR and make your own decisions.

I’d just say this to current holders and any new investors thinking of buying in for the first time.
Firstly, for those thinking there is not going to be any news from Hemogenyx for six months, that’s factually incorrect. What we do know from Vlad’s Webinar is that the Master Cell line work for their CDX Antibody in collaboration with Selexis will either be completed this month or next. This is important as a) it’s a major step forward in ensuring they have another candidate suitable for clinical trials b) there’s a fair chance that they’ll license it to someone to take it forward quickly c) if they don’t license it it’s probable there’s a collaboration with a partner and the chance of up front revenue. Secondly, we know Hemogenyx are working with an unnamed parter to prove CBR works in vitro, initially for the live virus of Covid. This work has been ongoing for a while now so it’s probable we’ll hear the results sooner rather than later. If the results are positive, it’s a potential paradigm shift in the treatment of all viral infections and a totally unique approach for the market. Again, successful results are very likely to have partners queuing up to either assist Hemogenyx taking it forward quickly or more likely to license it from Hemogenyx to take it forward themselves. As has been discussed, Hemogenyx might just license it for Covid and have the potential to license cures for other viral diseases to other partners, depending on how much someone is willing to pay for the technology. Lastly there is CAT-T, which we know is Hemogenyx main focus at the moment and Hemogenyx are doing everything possible to get their IND application completed in December. That being the case, it’s probable that if investors are waiting for this alone they’ll either be loading up in early December or maybe as soon as mid November. If it’s the latter then that’s barely over sixteen weeks away with updates on CDX and CBR to come beforehand. Add in potential partnerships, collaborations, licensing deals and non dilutive finance they’re working on, and the fact they are already fully funded for the next twelve months, I think the future is a lot rosier than some are making out. That’s why I bought more today anyway, and I’ll keep buying all the way down if holders don’t have the sticky fingers I have and it is a real pleasure taking them off you at these prices. Whatever you think of the above, DYOR and make your own decisions.

Bought another 316k at a great price. Was going to listen to the knowledge Tuan who surprisingly flits between knowing the English language and being illiterate (as if he were two people lol) but realised he knows absolutely **** all about Hemogenyx so bought another 316k instead. Remember CAR-T May be end of year but there’s still the CDX Master Cell line, CBR in vitro results and a potential non dilutive finance agreement to come